6547.TWO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 08:30):

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally...

Stats
Dzisiejszy wolumen	1.09M
Średni wolumen	1.41M
Kapitalizacja rynkowa	17.19B
EPS	TWD0 ( 2024-03-15 )
Następna data zysków	( TWD0 ) 2024-05-03
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-14.82
ATR14	TWD0.0660 (0.13%)

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: -0.45 (neutral)

Signal:(52.545) Neutral

Medigen Vaccine Biologics Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medigen Vaccine Biologics Korelacja - Waluta/Towar

-0.11
( neutral )

-0.17
( neutral )

0.00
( neutral )

-0.13
( neutral )

0.80
( strong )

0.37
( neutral )

Medigen Vaccine Biologics Finanse

Annual	2023
Przychody:	TWD389.62M
Zysk brutto:	TWD221.15M (56.76 %)
EPS:	TWD-3.53

FY	2023
Przychody:	TWD389.62M
Zysk brutto:	TWD221.15M (56.76 %)
EPS:	TWD-3.53

FY	2022
Przychody:	TWD365.04M
Zysk brutto:	TWD-212.60M (-58.24 %)
EPS:	TWD-4.64

FY	2021
Przychody:	TWD3.28B
Zysk brutto:	TWD2.31B (70.25 %)
EPS:	TWD5.09

Financial Reports:

No articles found.

Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.

Aktualne aktualizacje dla Medigen Vaccine Biologics [6547.TWO]

Upcoming Earnings Alert